Safety	O
and	O
toxicology	B:C0040541
of	O
the	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
siRNA	O
plasmid	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
.	O

Safety	O
and	O
toxicology	O
of	O
the	O
intravenous	B:C0013125
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
siRNA	O
plasmid	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
.	O

Safety	O
and	O
toxicology	O
of	O
the	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	B:C0540511
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
siRNA	O
plasmid	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
.	O

Safety	O
and	O
toxicology	O
of	O
the	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
siRNA	B:C1099354
plasmid	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
.	O

Safety	O
and	O
toxicology	O
of	O
the	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
siRNA	O
plasmid	B:C0032136
chitosan	O
magnetic	O
nanoparticles	I:C2713587
.	O

Safety	O
and	O
toxicology	O
of	O
the	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
siRNA	O
plasmid	O
chitosan	B:C0162969
magnetic	O
nanoparticles	I:C2713587
.	O

Safety	O
and	O
toxicology	O
of	O
the	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
siRNA	O
plasmid	O
chitosan	O
magnetic	B:C2713587
nanoparticles	I:C2713587
.	O

This	O
aim	O
of	O
the	O
present	O
study	B:C2603343
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	O
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	O
�€‘	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
(	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	B:C0040541
of	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	O
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	O
�€‘	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
(	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	B:C0013125
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	O
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	O
�€‘	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
(	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	B:C0540511
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	O
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	O
�€‘	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
(	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	B:C0540511
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	O
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	O
�€‘	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
(	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	B:C1099354
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	O
�€‘	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
(	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	O
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	B:C0032136
�€‘	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
(	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	O
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	O
�€‘	O
chitosan	B:C0162969
magnetic	O
nanoparticles	I:C2713587
(	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	O
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	O
�€‘	O
chitosan	O
magnetic	B:C2713587
nanoparticles	I:C2713587
(	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	O
administration	I:C0013125
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
(	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
)	O
�€	O
‘	O
small	O
interfering	I:C1099354
(	I:C1099354
si	I:C1099354
)	I:C1099354
RNA	I:C1099354
plasmid	O
�€‘	O
chitosan	O
magnetic	O
nanoparticles	I:C2713587
(	O
chitosan	B:C2713587
magnetic	I:C2713587
nanoparticles	I:C2713587
)	O
.	O

angiopoietin�	B:C0540511
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
were	O
constructed	O
and	O
subsequently	O
administered	O
at	O
different	O
doses	O
to	O
mice	O
and	O
rats	O
via	O
the	O
tail	O
vein	I:C2985205
.	O

angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	B:C2713587
magnetic	I:C2713587
nanoparticles	I:C2713587
were	O
constructed	O
and	O
subsequently	O
administered	O
at	O
different	O
doses	O
to	O
mice	O
and	O
rats	O
via	O
the	O
tail	O
vein	I:C2985205
.	O

angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
were	O
constructed	O
and	O
subsequently	O
administered	O
at	O
different	O
doses	O
to	O
mice	B:C0025929
and	O
rats	O
via	O
the	O
tail	O
vein	I:C2985205
.	O

angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
were	O
constructed	O
and	O
subsequently	O
administered	O
at	O
different	O
doses	O
to	O
mice	O
and	O
rats	B:C0034693
via	O
the	O
tail	O
vein	I:C2985205
.	O

angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
were	O
constructed	O
and	O
subsequently	O
administered	O
at	O
different	O
doses	O
to	O
mice	O
and	O
rats	O
via	O
the	O
tail	B:C2985205
vein	I:C2985205
.	O

The	O
acute	O
(	O
in	O
mice	B:C0025929
)	O
and	O
chronic	O
toxicity	O
(	O
in	O
rats	O
)	O
were	O
observed	O
.	O

The	O
acute	O
(	O
in	O
mice	O
)	O
and	O
chronic	O
toxicity	B:C0600688
(	O
in	O
rats	O
)	O
were	O
observed	O
.	O

The	O
acute	O
(	O
in	O
mice	O
)	O
and	O
chronic	O
toxicity	O
(	O
in	O
rats	B:C0034693
)	O
were	O
observed	O
.	O

The	O
results	O
of	O
the	O
acute	O
toxicity	B:C0022885
assay	I:C0022885
revealed	O
that	O
the	O
LD50	O
mice	O
was	O
>	O
707.0	O
mg·kg�	O
€	O
‘	O
1·d�	O
€	O
‘	O
1	O
,	O
and	O
the	O
general	O
condition	I:C1142435
of	O
mice	O
revealed	O
no	O
obvious	I:C3809765
abnormalities	I:C3809765
.	O

The	O
results	O
of	O
the	O
acute	O
toxicity	O
assay	I:C0022885
revealed	O
that	O
the	O
LD50	O
mice	B:C0025929
was	O
>	O
707.0	O
mg·kg�	O
€	O
‘	O
1·d�	O
€	O
‘	O
1	O
,	O
and	O
the	O
general	O
condition	I:C1142435
of	O
mice	O
revealed	O
no	O
obvious	I:C3809765
abnormalities	I:C3809765
.	O

The	O
results	O
of	O
the	O
acute	O
toxicity	O
assay	I:C0022885
revealed	O
that	O
the	O
LD50	O
mice	O
was	O
>	O
707.0	O
mg·kg�	O
€	O
‘	O
1·d�	O
€	O
‘	O
1	O
,	O
and	O
the	O
general	B:C1142435
condition	I:C1142435
of	O
mice	O
revealed	O
no	O
obvious	I:C3809765
abnormalities	I:C3809765
.	O

The	O
results	O
of	O
the	O
acute	O
toxicity	O
assay	I:C0022885
revealed	O
that	O
the	O
LD50	O
mice	O
was	O
>	O
707.0	O
mg·kg�	O
€	O
‘	O
1·d�	O
€	O
‘	O
1	O
,	O
and	O
the	O
general	O
condition	I:C1142435
of	O
mice	B:C0025929
revealed	O
no	O
obvious	I:C3809765
abnormalities	I:C3809765
.	O

The	O
results	O
of	O
the	O
acute	O
toxicity	O
assay	I:C0022885
revealed	O
that	O
the	O
LD50	O
mice	O
was	O
>	O
707.0	O
mg·kg�	O
€	O
‘	O
1·d�	O
€	O
‘	O
1	O
,	O
and	O
the	O
general	O
condition	I:C1142435
of	O
mice	O
revealed	O
no	B:C3809765
obvious	I:C3809765
abnormalities	I:C3809765
.	O

With	O
the	O
exception	O
of	O
the	O
high	O
dose	O
group	O
(	O
254.6	O
mg·kg	O
�	O
€	O
‘	O
1	O
·d�	O
€	O
‘	O
1	O
)	O
,	O
which	O
exhibited	O
partial	B:C0242073
lung	I:C0242073
congestion	I:C0242073
,	O
the	O
other	O
groups	O
exhibited	O
no	O
obvious	I:C3809765
abnormalities	I:C3809765
.	O

With	O
the	O
exception	O
of	O
the	O
high	O
dose	O
group	O
(	O
254.6	O
mg·kg	O
�	O
€	O
‘	O
1	O
·d�	O
€	O
‘	O
1	O
)	O
,	O
which	O
exhibited	O
partial	O
lung	I:C0242073
congestion	I:C0242073
,	O
the	O
other	O
groups	O
exhibited	O
no	B:C3809765
obvious	I:C3809765
abnormalities	I:C3809765
.	O

Results	O
of	O
the	O
chronic	O
toxicity	B:C0022885
assay	I:C0022885
demonstrated	O
that	O
the	O
non�€‘	O
toxic	O
dose	O
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
in	O
the	O
rat	O
was	O
>	O
35.35	O
mg·kg	O
�	O
€	O
‘	O
1	O
·d�	O
€	O
‘	O
1	O
for	O
14	O
days	O
.	O

Results	O
of	O
the	O
chronic	O
toxicity	O
assay	I:C0022885
demonstrated	O
that	O
the	O
non�€‘	O
toxic	O
dose	O
of	O
angiopoietin�	B:C0540511
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
in	O
the	O
rat	O
was	O
>	O
35.35	O
mg·kg	O
�	O
€	O
‘	O
1	O
·d�	O
€	O
‘	O
1	O
for	O
14	O
days	O
.	O

Results	O
of	O
the	O
chronic	O
toxicity	O
assay	I:C0022885
demonstrated	O
that	O
the	O
non�€‘	O
toxic	O
dose	O
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	B:C2713587
magnetic	I:C2713587
nanoparticles	I:C2713587
in	O
the	O
rat	O
was	O
>	O
35.35	O
mg·kg	O
�	O
€	O
‘	O
1	O
·d�	O
€	O
‘	O
1	O
for	O
14	O
days	O
.	O

Results	O
of	O
the	O
chronic	O
toxicity	O
assay	I:C0022885
demonstrated	O
that	O
the	O
non�€‘	O
toxic	O
dose	O
of	O
angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
in	O
the	O
rat	B:C0034693
was	O
>	O
35.35	O
mg·kg	O
�	O
€	O
‘	O
1	O
·d�	O
€	O
‘	O
1	O
for	O
14	O
days	O
.	O

The	O
rat	B:C0034693
general	O
condition	I:C1142435
and	O
blood	O
biochemistry	O
indexes	O
revealed	O
no	O
obvious	I:C3809765
abnormality	I:C3809765
.	O

The	O
rat	O
general	B:C1142435
condition	I:C1142435
and	O
blood	O
biochemistry	O
indexes	O
revealed	O
no	O
obvious	I:C3809765
abnormality	I:C3809765
.	O

The	O
rat	O
general	O
condition	I:C1142435
and	O
blood	O
biochemistry	O
indexes	O
revealed	O
no	B:C3809765
obvious	I:C3809765
abnormality	I:C3809765
.	O

The	O
blood	B:C0022885
routine	I:C0022885
indexes	I:C0022885
and	O
lung	O
/	I:C1261161
body	I:C1261161
ratio	I:C1261161
of	O
each	O
treatment	O
group	O
were	O
higher	O
when	O
compared	O
with	O
the	O
control	O
group	O
.	O

The	O
blood	O
routine	I:C0022885
indexes	I:C0022885
and	O
lung	B:C1261161
/	I:C1261161
body	I:C1261161
ratio	I:C1261161
of	O
each	O
treatment	O
group	O
were	O
higher	O
when	O
compared	O
with	O
the	O
control	O
group	O
.	O

The	O
middle�€	O
‘	O
and	O
high�€	O
‘	O
dose	O
groups	O
exhibited	O
chronic	O
pulmonary	B:C0242073
congestion	I:C0242073
,	O
whilst	O
the	O
low�€	O
‘	O
dose	O
and	O
control	O
groups	O
exhibited	O
no	O
abnormality	I:C3809765
.	O

The	O
middle�€	O
‘	O
and	O
high�€	O
‘	O
dose	O
groups	O
exhibited	O
chronic	O
pulmonary	O
congestion	I:C0242073
,	O
whilst	O
the	O
low�€	O
‘	O
dose	O
and	O
control	O
groups	O
exhibited	O
no	B:C3809765
abnormality	I:C3809765
.	O

Similarly	O
,	O
the	O
other	O
organs	B:C0003055
revealed	O
no	O
obvious	I:C3809765
abnormality	I:C3809765
.	O

Similarly	O
,	O
the	O
other	O
organs	O
revealed	O
no	B:C3809765
obvious	I:C3809765
abnormality	I:C3809765
.	O

angiopoietin�	B:C0540511
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
have	O
good	O
safety	O
at	O
a	O
certain	O
dose	O
range	O
and	O
may	O
be	O
considered	O
as	O
the	O
target	O
drug	O
carrier	I:C0013161
.	O

angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	B:C2713587
magnetic	I:C2713587
nanoparticles	I:C2713587
have	O
good	O
safety	O
at	O
a	O
certain	O
dose	O
range	O
and	O
may	O
be	O
considered	O
as	O
the	O
target	O
drug	O
carrier	I:C0013161
.	O

angiopoietin�	O
€	I:C0540511
‘	I:C0540511
2	I:C0540511
�€‘	O
chitosan	O
magnetic	I:C2713587
nanoparticles	I:C2713587
have	O
good	O
safety	O
at	O
a	O
certain	O
dose	O
range	O
and	O
may	O
be	O
considered	O
as	O
the	O
target	O
drug	B:C0013161
carrier	I:C0013161
.	O

